Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,290.00
Bid: 1,290.00
Ask: 1,296.00
Change: -8.00 (-0.62%)
Spread: 6.00 (0.465%)
Open: 1,272.00
High: 1,300.00
Low: 1,272.00
Prev. Close: 1,298.00
VCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Victrex plc - Q3 Interim Management Statement

6 Jul 2023 07:00

RNS Number : 1185F
Victrex PLC
06 July 2023
 
 

 

6 July 2023

Victrex plc - Q3 Interim Management Statement

Volumes lower on macro-economic weakness; further price improvement

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and bring environmental and societal benefit in multiple end-markets. Today's Interim Management Statement for Q3 covers the period 1 April 2023 to 30 June 2023.

Performance summary - Q3 in line with guidance

As previously communicated in our trading update of 14 June 2023 and at our interim results, compared to a record prior year period, the Group is seeing ongoing macro-economic weakness and destocking across several end markets.

The Group continues to be well positioned for a macro-economic recovery.

Q3 saw further improvement in average selling prices (ASP), taking year-to-date ASP to £85/kg, supported by price increases, sales mix and currency. We now anticipate that full year ASP will be above £84/kg. This in turn, together with easing energy costs, means we are seeing gross margin improvement during the second half, compared to the prior year, but it will be slightly held back by lower asset utilisation.

Further progress in mega-programmes; E-mobility exceeding expectations

Further progress was seen in commercial milestones within our 'mega-programme' growth pipeline, particularly in E-mobility and Trauma. We now anticipate annual revenues in our E-mobility mega-programme will exceed our original expectations, reaching £5m in FY 2023. In Trauma, we are making good progress with our PEEK composite Trauma plates, serving growing demand in the US and Asia. Run-rates are building towards £1m revenue and further growth in both E-mobility and Trauma is expected in FY 2024.

Q3 performance:

· Q3 Group revenue down 23% to £72.2m (Q3 2022: £93.4m)

· Q3 Group volume down 38% to 818 tonnes (Q3 2022: 1,323 tonnes)

· Year to date Group revenue of £234.4m is 8% down on the prior year (2022 YTD: £253.5m), with YTD Group volume of 2,759 tonnes being 23% down on the prior year (2022 YTD: 3,586 tonnes)

· Q3 weakness driven by Electronics, Energy & Industrial and Value Added Resellers

· Aerospace seeing good growth; Automotive stable YTD

· Medical performing strongly; YTD revenue continues to track up double-digit

 

 

 

Financial position

Victrex retains a highly cash generative business model, which supports growth investment and shareholder returns. Capital expenditure this year is focused on our China manufacturing investments, with our new PEEK polymer facility having delivered first polymer ahead of commercial start up by the end of 2023. Total cash on 30 June 2023 was £27m, which includes £3.5m cash ringfenced in China investments. Capital expenditure will start to step down from FY 2024, supporting improving cashflows.

 

Outlook unchanged

Jakob Sigurdsson, Chief Executive of Victrex, said: "In line with our recent trading update, we continue to be impacted by ongoing macro-economic weakness and destocking in several end markets. Compared to a record prior year period, lower Q3 volumes were driven by Electronics, Energy & Industrial and Value Added Resellers. Aerospace and Medical continue to perform strongly, whilst Automotive is stable year-to-date.

 

"Overall, our Outlook is unchanged from what we recently communicated, with full-year adjusted (pre-exceptional) PBT expected to be in the range of £80m-£85m. As we move into the final quarter, strong average selling prices, mix, energy costs and cost discipline remain supportive, and we continue to be well-placed for when the macro-economic environment improves.

 

"On a medium to long term basis, we have a strong and diverse core business, growing commercialisation in our mega-programmes, capital investment which is set to reduce and support improving cash flows, and strong ESG credentials."

 

Victrex will report its Preliminary Results for 2023 on Tuesday 4 December 2023.

 

Analyst & investor call:

A call for analysts & investors will be held today, Thursday 6 July, at 08.30am UK time. To register for the call please follow this link:

https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=3197336&linkSecurityString=82f3181b0

 

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

Ian Melling, Chief Financial Officer 

+44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTBCGDRISGDGXU
Date   Source Headline
5th May 20209:00 amRNSDirector Declaration
30th Apr 202011:39 amRNSTotal Voting Rights
17th Apr 202012:04 pmRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSMarket Update
3rd Apr 20207:00 amRNSDirector Declaration
31st Mar 20209:22 amRNSTotal Voting Rights
24th Mar 20202:00 pmRNSDirectorate Change
17th Mar 20203:32 pmRNSHolding(s) in Company
17th Mar 20202:52 pmRNSDirector/PDMR Shareholding
16th Mar 202010:05 amRNSHolding(s) in Company
12th Mar 202012:47 pmRNSDirector/PDMR Shareholding
3rd Mar 20209:49 amRNSDirector/PDMR Shareholding
28th Feb 202011:56 amRNSTotal Voting Rights
20th Feb 20204:50 pmRNSDirector/PDMR Shareholding
13th Feb 20201:59 pmRNSDirector/PDMR Shareholding
6th Feb 20202:34 pmRNSDirector/PDMR Shareholding
6th Feb 20201:20 pmRNSResult of AGM
6th Feb 202010:54 amRNSDirector/PDMR Shareholding
6th Feb 20207:00 amRNSAGM and Q1 Interim Management Statement
5th Feb 20204:22 pmRNSHolding(s) in Company
4th Feb 20203:42 pmRNSHolding(s) in Company
31st Jan 202010:39 amRNSTotal Voting Rights
20th Jan 202010:04 amRNSDirector/PDMR Shareholding
17th Jan 202010:38 amRNSDirector/PDMR Shareholding
13th Jan 20204:06 pmRNSHolding(s) in Company
13th Jan 20208:46 amRNSJoint Venture
3rd Jan 202012:00 pmRNSAnnual Financial Report
31st Dec 20199:00 amRNSTotal Voting Rights
23rd Dec 20191:44 pmRNSHolding(s) in Company
17th Dec 20192:20 pmRNSDirector/PDMR Shareholding
12th Dec 201910:04 amRNSDirector/PDMR Shareholding
5th Dec 20197:00 amRNSPreliminary Results 2019
2nd Dec 20191:52 pmRNSBlock listing Interim Review
29th Nov 201911:38 amRNSTotal Voting Rights
19th Nov 201911:02 amRNSDirector/PDMR Shareholding
12th Nov 201912:00 pmRNSDirectorate Change
31st Oct 201911:36 amRNSTotal Voting Rights
28th Oct 20191:41 pmRNSHolding(s) in Company
18th Oct 20194:01 pmRNSHolding(s) in Company
18th Oct 20192:20 pmRNSDirector/PDMR Shareholding
16th Oct 201911:04 amRNSAdditional Listing
11th Oct 20194:18 pmRNSHolding(s) in Company
8th Oct 20193:09 pmRNSHolding(s) in Company
7th Oct 20194:06 pmRNSHolding(s) in Company
3rd Oct 20194:18 pmRNSHolding(s) in Company
30th Sep 201911:53 amRNSTotal Voting Rights
18th Sep 20199:19 amRNSDirector/PDMR Shareholding
30th Aug 20199:00 amRNSTotal Voting Rights
19th Aug 201911:44 amRNSDirector/PDMR Shareholding
14th Aug 201910:39 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.